Rationale for phase III trials of thoracic radiation therapy doses in limited-stage small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 4, 2008, Pages 202-205

  Bogart, Jeffrey A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Accelerated radiotherapy; Concurrent chemotherapy; Dose escalation; Topoisomerase I inhibitor

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; HUMAN; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; THORAX RADIOGRAPHY;

EID: 49349105081     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.029     Document Type: Review

References (31)

1. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-24.
2. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890-5.
3. Janne PA, Freidlin B, Saxman S, et al. The survival of patients treated for limited stage small cell lung cancer in North America has increased during the past 20 years. Proc Am Soc Clin Oncol 2001; 20:317a (Abstract 1264).
4. Sansom D, Seidenfeld J, Simpson G, et al. Evidence for management of small cell lung cancer. Chest 2007; 132:314S-23S.
5. Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphologic varianrs. Cancer Res 1983; 43:2806-11.
6. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-71.
7. Movsas B, Moughan J, Komaki R, et al. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 2003; 21:4553-9.
8. Choi NC, Herndon II JE, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small cell lung cancer. J Clin Oncol 1998; 16:3528-36.
9. Choi NC, Herndon J, Rosenman J, et al. Long term survival data from CALGB 8837: radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC). Possible radiation dose-survival relationship. Proc Am Soc Clin Oncol 2002; 21:1190 (Abstract 1190).
10. Bogart JA, Herndon JE, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited stage small cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004; 59:460-8.
11. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48:7-16.
12. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 2005; 62:342-50.
13. National Cancer Institute [Web site]. Phase II study of cisplatin and etoposide combined with accelerated high-dose thoracic radiotherapy in patients with limited stage small cell lung cancer. Available at: http://www.nci.nih.gov/ clinicaltrials. Accessed: May 10, 2008.
14. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Brit J Radiol 1989; 62:679-94.
15. Perry MC, Herndon JE, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol 1998; 16:2466-7.
16. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993; 11:336-44.
17. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054-60.
18. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-srage small-cell lung cancer. J Clin Oncol 2004; 22:4837-45.
19. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006; 17:543-52.
20. Einhorn LH. Initial therapy with cisplatin plus VP-16 in small-cell lung cancer. Semin Oncol 1986; 13:5-9.
21. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-91.
22. Niell HB, Herndon JE II, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23:3752-9.
23. Ettinger DS, Berkey BA, Abrams RA, et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 2005; 23:4991-8.
24. Lyss AP, Herndon J, Lynch T, et al. Novel doublets in extensive stage small cell lung cancer: A randomized phase II study of toporecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 2002; 3:205-10.
25. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
26. Hanna N, Bunn PA Jr, Langer C, etal. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006; 24:2038-43.
27. Langer CJ, Swamm S, Werner-Wasik R, et al. Phase I study of irinotecan (lr) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241. J Clin Oncol 2006; 24(18 suppl):378s (Abstract 7058).
28. Bradley JD, Graham M, Suzanne S, et al. Phase I results of RTOG 0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable non-small cell lung cancer. J Clin Oncol 2005; 24(16 suppl):636s (Abstract 7063).
29. Bogart JA, Govindan R. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. Clin Lung Cancer 2006; 7:285-7.
30. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25:1698-704.
31. Curran WJ, Scott CB, Langer, CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22:621a (Abstract 2499).